Screener
Climb Bio, Inc. CLYM Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in investing activities | (12,955) | (42,751) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 5 | — |
| Net cash provided by financing activities | 5 | — |
| Effect of exchange rate changes on cash and cash equivalents | — | (24) |
| Net change in cash and cash equivalents | (27,329) | (58,209) |
| Cash and cash equivalents at beginning of period | 35,685 | 87,229 |
| Cash and cash equivalents at end of period | $8,356 | $29,020 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s financing cash flow?
- Climb Bio, Inc. (CLYM) reported financing cash flow of $5K in Q1 2026.
- What is the long-term trend for Climb Bio, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s financing cash flow has grown at a -89.6% compound annual growth rate (CAGR), from $177.23M to -$21K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Climb Bio, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude